Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population
Authors:
Open Access
- 6 January 2016
- journal article
- review article
- Published by Springer Nature in Cardiology and Therapy
- Vol. 5 (1) , 19-41
Abstract
Common treatment options for deep vein thrombosis and venous thromboembolism in the pediatric population include unfractionated heparin, low molecular weight heparin, and warfarin. Other alternatives are bivalirudin, argatroban, and fondaparinux. Warfarin is the only approved oral option, but an oral agent without frequent monitoring would be optimal for pediatric patients. Thus, there is an increasing need for new anticoagulation options in this population. None of the current direct oral anticoagulants have FDA-approved indications and dosing in children. The two classes of DOACs and the drugs they are comprised of are factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and direct thrombin inhibitor (dabigatran). Off-label usage of these agents is largely based on adult doses. By far, rivaroxaban and dabigatran have the most published data and ongoing trials in pediatric patients compared to edoxaban and apixaban. After evaluating the current literature available on these agents, it is, however, still too early to make any definitive recommendations on their usage in this special population.Keywords
This publication has 35 references indexed in Scilit:
- Assessing the anticoagulant effect of dabigatran in children: An in vitro studyThrombosis Research, 2015
- Antithrombotic Therapy in Neonates and ChildrenChest, 2012
- FondaKIDS: A prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of agePediatric Blood & Cancer, 2011
- Treatment of Thrombosis With Fondaparinux (Arixtra) in a Patient With End-stage Renal Disease Receiving Hemodialysis TherapyJournal of Pediatric Hematology/Oncology, 2007
- Pediatric Experience with Fondaparinux in Deep Venous Thrombosis.Blood, 2006
- Recognition and Management of Heparin-Induced Thrombocytopenia in Pediatric Cardiopulmonary Bypass PatientsThe Annals of Thoracic Surgery, 2006
- Argatroban use during pediatric interventional cardiac catheterizationCatheterization and Cardiovascular Interventions, 2003
- Anticoagulation with Recombinant Hirudin and Danaparoid Sodium in Pediatric PatientsSeminars in Thrombosis and Hemostasis, 2002
- Lepirudin anticoagulation for heparin-induced thrombocytopeniaThe Journal of Pediatrics, 2002
- CLINICAL APPLICATION OF ARGATROBAN AS AN ALTERNATIVE ANTICOAGULANT FOR EXTRACORPOREAL CIRCULATIONHematology/Oncology Clinics of North America, 2000